Oclassen Pharmaceuticals Inc. of San Rafael, Calif., hasreceived an exclusive license from Eli Lilly & Co. to distributeLilly's Cordran and Cinobac products in North America.

Cordran products are topical corticosteroids for the treatmentof skin inflammation and include the only steroid-impregnatedtape marketed in the U.S. and Canada, which provides superiorlocalization of anti-inflammatory therapy.

Cinobac is an oral quinolone antibiotic for the treatment ofurinary tract infections.

Oclassen will pay Lilly a manufacturing profit and futureroyalties based on sales.

The distribution agreement also provides Oclassen with "rightsof first discussion" for other Lilly products that it chooses toout-license.

Oclassen develops and markets pharmaceuticals for thetreatment of bacterial and viral diseases with a primary focuson dermatology, virology and sexually transmitted diseases.

(c) 1997 American Health Consultants. All rights reserved.